Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

         
Date of Report (Date of earliest reported)   August 22, 2001
   
         
    Advanced Biotherapy, Inc.
(Exact name of registrant as specified in its chapter)
   
         
Delaware   0-26323   95-0402415

 
 
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
         
6355 Topanga Canyon Boulevard, Suite
510; Woodland Hills, California
(Address of principal executive offices)
  91367
(Zip Code)
   
         
Registrant’s telephone number, including area code   (818) 883-6716
   

 


TABLE OF CONTENTS

Item 5. OTHER EVENTS.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
Signatures
INDEX TO EXHIBITS
EXHIBIT 99.1

Item 5. OTHER EVENTS.

     The registrant published a press release as of August 20, 2001, which announced that the registrant has received a “Notice of Allowance” from the United States Patent and Trademark Office for a utility patent for an antibody to treat autoimmune diseases. A copy of such press release is incorporated herein by reference and is attached as an exhibit to this Form 8-K.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS

(c)   Exhibits.

   
Designation Description of Exhibit
99.1 Press Release, dated August 20, 2001

Signatures

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
  ADVANCED BIOTHERAPY, INC.
(Registrant)
 
 
 
Date: August 22, 2001 By:  /s/ Edmond Buccellato
       
  Edmond Buccellato, President

INDEX TO EXHIBITS

     
Exhibit   Description

 
99.1   Text of Press Release, dated August 20, 2001